– Reuters
Annovis Bio Announces Statistically Significant Phase II/III Data In Patients With Early Alzheimer’s Disease; Efficacy In The CGIC Endpoint Was Not Reached Due To The Limited Number Of Patients And Short Trial Duration
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as
